ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
亞盛醫藥
17.38
+0.0000
成交量:
- -
成交額:
3,817.09萬
市值:
14.94億
市盈率:
- -
高:
17.38
開:
17.38
低:
17.38
收:
17.38
資料載入中...
總覽
公司
新聞
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞
【券商聚焦】東吳證券維持亞盛醫藥(06855)“買入”評級 指海外市場潛力較大 預計收入將快速增長
金吾财讯
·
01-28
亞盛醫藥下跌2.18%,報17.001美元/股
金融界
·
01-28
方正證券:維持亞盛醫藥-B(06855)“強烈推薦”評級 公司赴美上市進一步打通美國融資渠道
智通财经
·
01-27
亞盛醫藥-B(06855)根據承銷協議發行2930萬股
智通财经网
·
01-27
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPGV"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPGV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPGV\",,,,,undefined,":{"symbol":"AAPGV","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":17.38,"timestamp":1737752400000,"preClose":17.38,"halted":8,"volume":0,"delay":0,"floatShares":7325000,"shares":85988600,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"05-07 13:47:18 EDT","open":17.38,"high":17.38,"low":17.38,"amount":38170939.23419999,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1746648000000},"marketStatusCode":2,"symbolChange":{"newSymbol":"AAPG","executeDate":"2025-01-27"},"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":17.38,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPGV\",,,,,undefined,":{"symbol":"AAPGV","floatShares":7325000,"roa":"--","roe":"--","lyrEps":0,"shares":85988600,"dividePrice":0,"high":17.38,"amplitude":0,"preClose":17.38,"low":17.38,"week52Low":16.5,"pbRate":"--","week52High":18,"institutionHeld":0,"latestPrice":17.38,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":17.38},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AAPGV\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPGV\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506559657","title":"【券商聚焦】東吳證券維持亞盛醫藥(06855)“買入”評級 指海外市場潛力較大 預計收入將快速增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2506559657","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506559657?lang=zh_tw&edition=fundamental","pubTime":"2025-01-28 10:34","pubTimestamp":1738031679,"startTime":"0","endTime":"0","summary":"其中,耐立克已在国内获批上市,海外权益授权武田,开启重磅全球合作。此外,耐立克已获FDA批准在美国开展III期注册临床,预计25年完成患者入组,26年在美国递交上市申请。APG-115是首个在国内进入临床阶段的MDM2-p53抑制剂,联合用药潜力较大。考虑公司收入增长较快,海外市场潜力较大,维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","AAPG","AAPGV","601555"],"gpt_icon":0},{"id":"2506302192","title":"亞盛醫藥下跌2.18%,報17.001美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2506302192","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506302192?lang=zh_tw&edition=fundamental","pubTime":"2025-01-28 00:41","pubTimestamp":1737996097,"startTime":"0","endTime":"0","summary":"1月28日,亚盛医药(AAPG)盘中下跌2.18%,截至00:41,报17.001美元/股,成交130.83万美元。财务数据显示,截至2024年06月30日,亚盛医药收入总额8.24亿人民币,同比增长477.25%;归母净利润1.63亿人民币,同比增长140.51%。大事提醒:1月24日,亚盛医药于2025-01-24调整为1ADS等于4普通股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/28004147864327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","AAPGV"],"gpt_icon":0},{"id":"2506315428","title":"方正證券:維持亞盛醫藥-B(06855)“強烈推薦”評級 公司赴美上市進一步打通美國融資渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2506315428","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506315428?lang=zh_tw&edition=fundamental","pubTime":"2025-01-27 09:47","pubTimestamp":1737942469,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,方正证券发布研报称,1月24日,亚盛医药-B成功登录纳斯达克上市,此次公司登录美股募资约1.26亿美元,进一步打通了美国融资渠道,获得了新的资金支持,为后续产品发展提供了更多资源和确定性,有望加速奥雷巴替尼的全球商业化进展以及其他管线的研发进度。方正证券主要观点如下:事件:亚盛医药于2025年1月24日在美国纳斯达克正式上市,股票代码为AAPG。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1244357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601901","AAPGV","AAPG","06855"],"gpt_icon":0},{"id":"2506368310","title":"亞盛醫藥-B(06855)根據承銷協議發行2930萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2506368310","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506368310?lang=zh_tw&edition=fundamental","pubTime":"2025-01-27 08:03","pubTimestamp":1737936189,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)发布公告,于2025年1月24日根据2025年1月23日...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_31.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_31.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1244311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["AAPG","06855","AAPGV","BK1574","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPGV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-27","symbol":"AAPGV","oldSymbol":"AAPGV","defaultRemindTime":1737988200000,"newSymbol":"AAPG","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1737954000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPGV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPGV\",market:\"US\",delay:false,,,undefined,":{}}}